ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion: new indication

Lenacapavir (Sunlenca)

New indication (HIV Infections). The wording is on the EMA page.

CHMP opinion 12 Nov 2026 · Gilead Sciences Ireland Unlimited Company
EU · EU licence (European Commission)

Lenacapavir (Yeytuo)

Yeytuo tablet is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents with increased HIV 1 acquisition risk, weighing at least 35 kg for: oral loading oral bridging (see sections 4.2, 4.4 and 5.1) 

CHMP opinion 24 Jul 2025 → EU licence 25 Aug 2025 · Gilead Sciences Ireland Unlimited Company

Research

Infectious diseases · Lancet · 2026-08-12

In 626 virologically suppressed adults with HIV-1, switching to once-weekly oral islatravir-lenacapavir was non-inferior to continuing daily standard of care: HIV-1 RNA ≥50 copies/mL at week 48 in 0·3% vs 1·3%. Treatment-related adverse events 18% vs <1%.

RCTn = 634
Colson et al. Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial
Infectious diseases · Lancet HIV · 2026-07-13

Secondary analysis of phase 3 PURPOSE 1: in 487 women aged 16–25 who became pregnant, lenacapavir PrEP vs daily oral emtricitabine-tenofovir had balanced adverse events, similar pregnancy losses, unchanged drug exposure in pregnancy and minimal infant plasma levels.

Secondary analysisn = 487
Bekker et al. HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.